The Nervous System, Decoded
Nervous System
Science for the
Informed Human.
Your nervous system shapes everything — how you feel pain, how you sleep, how you heal. We break down the science, evaluate the products, and follow the money. No sponsors. No ads.
Start Here
The science behind your nervous system — how it regulates, recovers, and adapts.
Nervous System
How your body regulates itself.
Explore⚡Pain Science
Pain is a brain output, not an input.
Explore🌬️Breathwork
The one autonomic lever you can pull.
Explore🔄Recovery
What actually moves the needle.
Explore🌙Sleep
Architecture matters more than hours.
Explore📊Wearables
Evidence-based reviews, no sponsorships.
Explore
Start Here
Your nervous system, decoded.
Guides
The science behind stress, sleep, pain, and recovery — explained for real people.
🔬Research
New studies, clinical trials, and breakthroughs in neuroscience, psychedelics, and wearable tech.
🛡️Reviews
Independent, evidence-based product reviews. No sponsors, no ads, no affiliate links.
💰Funding
Who's raising capital in nervous system health, neurotech, and digital therapeutics.
Fresh Off the Wire
What's New
Aneuvo raises $22M Series C for ECAP-sensing spinal cord stimulation — ExaStim heads to FDA
Aneuvo closed a $22 million Series C in March 2026 for ExaStim, an ECAP-sensing spinal cord stimulation system for chronic pain. FDA 510(k) submitted May 2026.
Aurenar raises $5.7M seed to bring vagus nerve stimulation into the ICU for inflammation
Aurenar closed an oversubscribed $5.7 million seed round in July 2026 to advance V-Link, a non-invasive taVNS device for ICU inflammation. FDA Breakthrough Device designation granted June 2026.
Nervonik closes $52.5M Series B for closed-loop peripheral nerve stimulation for chronic pain
Nervonik closed an oversubscribed $52.5 million Series B in April 2026 for its miniaturized, wireless, closed-loop peripheral nerve stimulation platform for chronic neuropathic pain.
FDA finalizes psychedelic-assisted therapy guidance and schedules public hearing for September 2026
The FDA has finalized its industry guidance document for psychedelic-assisted therapy clinical trials and scheduled a public hearing for September 2026 to address regulatory framework questions. The guidance clarifies clinical trial design, therapist training, and safety monitoring requirements...
Microbiome-informed precision psychiatry: the NUTRIMIND initiative uses AI and multi-omics to map gut-brain-mental health interactions
The EU-funded NUTRIMIND initiative, launched in mid-2026, combines artificial intelligence with multi-omics analysis to study how nutrition, the gut microbiome, lifestyle factors, and mental health interact across the lifespan. The project aims to establish microbiome-informed precision psychiatry as a clinical framework...
Understanding the parasympathetic rebound: why you feel better after cold exposure
Cold exposure triggers an immediate sympathetic nervous system spike — elevated heart rate, vasoconstriction, catecholamine release. But the real therapeutic value lies in what happens after: a parasympathetic rebound where vagal tone overshoots baseline, producing the calm clarity practitioners report...
Evidence-Based. Not Sponsored.
Product Reviews
Flow FL-100 — The First FDA-Approved At-Home Brain Stimulation Device for Depression
Flow FL-100 is the first at-home tDCS device with full FDA premarket approval for treating major depressive disorder. In its Empower trial, 57.5% of participants achieved remission after 10 weeks. Launching in the US September 2026 as a prescription-only alternative or adjunct to antidepressants.
LumiSleep — The Closed-Loop EEG Headband That Guides Your Brain Into Sleep
LumiSleep by LumiMind uses a 7-point EEG electrode array to detect your brain's pre-sleep neural signature, then delivers adaptive acoustic pulses in real time to accelerate sleep onset. Launched at CES 2026, it represents a shift from passive sleep tracking to active sleep intervention.
Modius Spero — The First FDA-Cleared Neuromodulation Device for PTSD
Modius Spero is the first neuromodulation device FDA-authorized specifically to treat PTSD symptoms. Using vestibular nerve stimulation behind the ears, the prescription headset delivered clinically meaningful improvement in two-thirds of participants in a 383-person sham-controlled trial. Now rolling out through the VA.
Peer-Reviewed
From the Lab
AI model predicts over 130 health conditions from overnight sleep recordings years before symptom onset
A Stanford Medicine study published in Nature Medicine demonstrated an AI model capable of analyzing overnight sleep polysomnography recordings to predict the risk of over 130 health conditions — including cardiac, neurological, and respiratory disorders — often years before clinical symptoms appear...
Closed-loop adaptive deep brain stimulation adjusts in real time to neural signatures in Parkinson's disease
Multiple research sites in 2026 are advancing closed-loop adaptive deep brain stimulation for Parkinson's disease, where the device reads neural signatures in real time and adjusts stimulation parameters automatically. This approach reduces side effects and improves motor control compared to conventional continuous DBS...
Home-based transcutaneous auricular vagus nerve stimulation reduces anxiety severity and improves heart rate variability in generalized anxiety disorder
A feasibility study published in June 2026 investigated home-based transcutaneous auricular vagus nerve stimulation for generalized anxiety disorder. Participants using daily 30-minute taVNS sessions showed significant reductions in clinician-rated anxiety severity and improvements in heart rate variability metrics over 8 weeks...
Who's Raising
Capital in the Space
Aneuvo raises $22M Series C for ECAP-sensing spinal cord stimulation — ExaStim heads to FDA
Aneuvo closed a $22 million Series C in March 2026 for ExaStim, an ECAP-sensing spinal cord stimulation system for chronic pain. FDA 510(k) submitted May 2026.
Aurenar raises $5.7M seed to bring vagus nerve stimulation into the ICU for inflammation
Aurenar closed an oversubscribed $5.7 million seed round in July 2026 to advance V-Link, a non-invasive taVNS device for ICU inflammation. FDA Breakthrough Device designation granted June 2026.
Nervonik closes $52.5M Series B for closed-loop peripheral nerve stimulation for chronic pain
Nervonik closed an oversubscribed $52.5 million Series B in April 2026 for its miniaturized, wireless, closed-loop peripheral nerve stimulation platform for chronic neuropathic pain.
Coming Soon
The Body Mind State Project
Deep conversations with researchers, clinicians, and the brands actually doing the work. Science you can feel.
Launching 2026
Stay Regulated
Regulate your nervous system
from the inside out.
New research, honest product reviews, neurotech funding rounds, and events — delivered weekly, with zero sponsors or ads.